Novogen Limited Company Profile (NASDAQ:NVGN)

About Novogen Limited (NASDAQ:NVGN)

Novogen Limited logoNovogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVGN
  • CUSIP: N/A
  • Web:
  • Market Cap: $17 million
  • Outstanding Shares: 19,331,000
Average Prices:
  • 50 Day Moving Avg: $0.90
  • 200 Day Moving Avg: $1.33
  • 52 Week Range: $0.70 - $2.44
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -44.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.68 million
  • Price / Sales: 4.62
  • Book Value: $1.25 per share
  • Price / Book: 0.70
  • EBIDTA: ($8,130,000.00)
  • Net Margins: -2,919.56%
  • Return on Equity: -25.44%
  • Return on Assets: -20.66%
  • Current Ratio: 9.80%
  • Average Volume: 40,250 shs.
  • Beta: -0.37
  • Short Ratio: 0.84

Frequently Asked Questions for Novogen Limited (NASDAQ:NVGN)

What is Novogen Limited's stock symbol?

Novogen Limited trades on the NASDAQ under the ticker symbol "NVGN."

Where is Novogen Limited's stock going? Where will Novogen Limited's stock price be in 2017?

1 brokers have issued 12 month target prices for Novogen Limited's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Novogen Limited's share price to reach $5.00 in the next year. View Analyst Ratings for Novogen Limited.

Are investors shorting Novogen Limited?

Novogen Limited saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 26,107 shares, an increase of 117.1% from the April 28th total of 12,027 shares. Based on an average trading volume of 34,971 shares, the short-interest ratio is presently 0.7 days.

Who are some of Novogen Limited's key competitors?

Who are Novogen Limited's key executives?

Novogen Limited's management team includes the folowing people:

  • James B. Garner, Chief Executive Officer, Executive Director
  • Gordon Hirsch, Chief Medical Officer
  • Lilischkis Kimberley, Clinical & Regulatory Affairs Manager
  • Peng K. Leong, Chief Business Officer
  • Stephen Palmer, Program Director - Degenerative Diseases
  • Justine R. Stehn Ph.D., Director - ATM Program
  • Kate Hill, Interim Company Secretary
  • Iain Ross, Non-Executive Chairman of the Board
  • Bryce Carmine, Non-Executive Deputy Chairman of the Board
  • Steven Roy Stent Coffey, Non-Executive Director

Who owns Novogen Limited stock?

Novogen Limited's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.71%) and Morgan Stanley (0.66%). View Institutional Ownership Trends for Novogen Limited.

Who bought Novogen Limited stock? Who is buying Novogen Limited stock?

Novogen Limited's stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Novogen Limited.

How do I buy Novogen Limited stock?

Shares of Novogen Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novogen Limited's stock price today?

One share of Novogen Limited stock can currently be purchased for approximately $0.88.

MarketBeat Community Rating for Novogen Limited (NASDAQ NVGN)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Novogen Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novogen Limited (NASDAQ:NVGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (468.18% upside)

Analysts' Ratings History for Novogen Limited (NASDAQ:NVGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/28/2017HC WainwrightSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 6/28/2015 forward)


Earnings History for Novogen Limited (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by


Earnings Estimates for Novogen Limited (NASDAQ:NVGN)
Current Year EPS Consensus Estimate: $-0.02 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS


Dividend History for Novogen Limited (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Novogen Limited (NASDAQ:NVGN)
No insider trades for this company have been tracked by


Headline Trends for Novogen Limited (NASDAQ:NVGN)
Latest Headlines for Novogen Limited (NASDAQ:NVGN)
DateHeadline logoNovogen announces changes in the Board of Directors and a cost reduction program - June 9 at 12:50 AM logoShort Interest in Novogen Limited (NVGN) Increases By 117.1% - June 4 at 11:34 AM logoHead to Head Contrast: Shire PLC (SHPG) & Novogen Limited (NVGN) - June 3 at 10:40 PM logoNovogen Limited (NVGN) Earning Somewhat Negative Media Coverage, Study Shows - May 3 at 8:54 AM logoNovogen Limited (NVGN) Rating Lowered to Hold at Zacks Investment Research - May 3 at 7:50 AM logoNovogen Limited (NVGN) Earns Media Sentiment Rating of 0.31 - April 29 at 12:54 AM logoNovogen Limited (NVGN) Getting Somewhat Critical News Coverage, Study Finds - April 13 at 12:50 PM logoNovogen bags development of Anisina - April 7 at 11:36 AM logoZacks: Novogen Limited (NVGN) Given $5.00 Average Price Target by Brokerages - April 4 at 12:46 AM logoNovogen Receives $4.4M R&D Tax Rebate - March 27 at 10:02 AM logoTransformation to a Clinical Stage Organisation Leads to Changes in Management Structure - March 9 at 11:48 PM logoNovogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program - March 6 at 8:03 AM logoNovogen nabs $3M grant to fund new cancer therapies; shares up 5% - February 10 at 1:03 AM logo5:43 pm Novogen awarded grant of up to AUD $3 mln by the Australian federal government to fund development of a next-generation anti-tropomyosin program - February 8 at 7:50 PM logoNovogen (NVGN) Acquires Australian Biotech Company Glioblast Pty - November 2 at 6:51 PM logoNovogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma - October 31 at 1:07 PM logoNovogen Limited (NVGN) Down on Glioblast Purchase - October 31 at 1:07 PM logoNovogen ups commitment to brain cancer with acquisition of Glioblast and license of product candidate GDC-0084 from Genentech - October 31 at 1:07 PM logo1:20 am Novogen announces the licensing of GDC-0084; ready to enter a phase II clinical trial in glioblastoma multiforme - October 31 at 1:07 PM logoConversion of Convertible Notes - September 14 at 10:47 AM logoNovogen (NVGN) Hikes on FDA Nod - September 12 at 11:06 AM logoUS FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer - September 12 at 11:06 AM logoNovogen secures key US drug study approval - September 12 at 11:05 AM logoNovogen Submits IND Application For Cantrixil In Ovarian Cancer To FDA - August 12 at 9:46 AM logoNovogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer - August 11 at 9:46 AM logoNovogen Patent Covering Anisina(TM) Has Proceeded to Grant - June 13 at 8:30 PM logoNovogen Provides Update On Development Of Cantrixil - PR Newswire (press release) - May 3 at 2:24 PM logoNovogen Provides Update On Development Of Cantrixil - May 1 at 10:43 PM logoAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking Alpha - April 27 at 2:54 PM logoNovogen appoints new CEO - December 9 at 7:56 PM logoNovogen Appoints Dr James Garner as Chief Executive Officer - December 9 at 4:59 PM logoNOVOGEN LTD Financials - December 8 at 1:16 PM logoNovogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial - November 23 at 7:38 PM logoNovogen Patent Covering Cantrixil and Trilexium Accepted in Australia - November 11 at 7:04 PM logoPreclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina - November 10 at 5:34 PM logoNovogen Applies for Long-Term Options Listing on ASX - September 30 at 6:18 AM



Novogen Limited (NVGN) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by Staff